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A B S T R A C T
In 2017, Italy experienced one of the largest outbreaks of measles in recent years, with 5404 notiﬁed cases
and 4347 conﬁrmed cases. A further 2029 cases were notiﬁed during the ﬁrst 6 months of 2018, and 1516
of them were laboratory-conﬁrmed. The B3 and D8 genotypes were identiﬁed as those responsible for the
outbreak. Possible transmission routes can be established by monitoring the circulating measles virus
strains in support of the national health authorities to warn people and travellers.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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journal home page: www.elsevier .com/ locat e/ i j idAfter the large epidemic of measles in 2017, with 5404 notiﬁed
cases and 4347 conﬁrmed cases, between January 1 and June 30,
2018, 2029 cases of measles were reported to the Italian national
measles and rubella surveillance system. Of these, 1516 (75%) were
laboratory-conﬁrmed in accordance with the World Health
Organization (WHO) guidelines, as described previously (Istituto
Superiore di Sanità (ISS), 2018a; Magurano et al., 2015). The
outbreak reached its peak in the month of April 2018, with 466
cases (Figure 1), and showed slight signs of a turnaround at the
time of writing this article.
Among 2029 notiﬁed cases, 1516 (74.7%) were laboratory-
conﬁrmed in accordance with the WHO guidelines, by molecular
(n = 540) or serological methods (n = 976), at the National Refer-
ence Laboratory (Magurano et al., 2015) and the Network of Italian
Reference Laboratories for Measles and Rubella (MoRoNet)
(Istituto Superiore di Sanità (ISS), 2018b). Among the PCR-positive
samples, 338 sequences were obtained by amplifying a fragment of
the carboxyl-terminal coding region of the N gene, including the
450-bp fragment recommended for genotyping (Magurano et al.,
2015; World Health Organization, 2012a), and were analysed* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).phylogenetically. All sequences were submitted to the Measles
Nucleotide Surveillance (MeaNS) database (Rota et al., 2011).
The analysis of the sequences identiﬁed in Italy during the ﬁrst
half of 2018 demonstrated the co-circulation of genotypes B3 and
D8, with 272 and 66 sequences identiﬁed, respectively.
BLAST analysis in MeaNS established that among the sequences
belonging to genotype B3, 157 were identical to the WHO named
strain MVs/Dublin.IRL/8.16, also responsible for several outbreaks
in Europe. MVs/Dublin.IRL/8.16 has been circulating in Italy since
2017. Evidence of the introduction of this strain to Italy dates back
to the end of 2016, and it occurred as a result of several
importations in Northern Italy from Romania, as supported by
epidemiological data. Fifty-nine B3 sequences were identical to the
WHO strain MVs/SaintDenis.FRA/36.17/. This strain has been
circulating in Italy since 2017, but there are no epidemiological
data to support the hypothesis of importation from abroad. Ten
sequences were identical to the WHO strain MVs/Ljubljana.SVN/
27.17/. Evidence of importation from the Czech Republic was
provided for nine of these sequences.
Beyond these variants, the remaining 46 sequences classiﬁed as
B3, but not identical to any of the WHO strains, were closely related
to the B3 strains included in Figure 2: 20 were closely related to
strain MVs/Dublin.IRL/8.16, one to MVs/SaintDenis.FRA/36.17,
eight to MVs/Islamabad.PAK/1.13/, and 17 to MVs/Kabul.AFG/
20.2014/3. For several of these cases, evidence of importation wasciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Reported measles cases by month of rash onset, Italy, January 2016 – June 2018 (n = 8 291).
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abroad (countries of origin are reported in Figure 2 in brackets).
Among the 66 sequences belonging to genotype D8, 15 were
identical to WHO named strain MVs/GirSomnath.IND/42.16/, nine
were identical to MVs/Herborn.DEU/05.17/, three to MVs/Victoria.
AUS/6.11/, and four to MVs/Cambridge.GBR/5.16/. The introduction
of strain MVs/Herborn.DEU/05.17/into Italy dates back to two
importation events. The ﬁrst event was linked to four patients
returning from England (February 2018). The second one was
linked to a patient who had travelled in Switzerland (April 2018).
The named strain MVs/Victoria.AUS/6.11/was identiﬁed in two
patients who had travelled in Thailand (May 2018), suggesting the
introduction of this strain from the Orient. Named strain MVs/
GirSomnath.IND/42.16/was identiﬁed in a patient returning from
Germany. MVs/Cambridge.GBR/5.16/was identiﬁed in two patients
returning from Ukraine.
The remaining 35 sequences were not identical to any of the D8
named strains. Twenty-two were closely related to MVs/Frank-
furtMain.DEU/17.11, four to MVs/Gadag.IND/02.13, four to MVs/
Victoria.AUS/6.11, two to MVs/Thiruvananthapuram.IND/18.12, one
to MVs/Herborn.DEU/05.17/, and two to MVs/Cambridge.GBR/5.16/
. Evidence of importations was established by epidemiological
links to patients returning from abroad (countries of origin are
reported in Figure 2 in brackets).
According to the MeaNS database, many European countries
have reported the dominance of B3 and D8 measles strains in 2018.
Italian epidemiological data indicate that several cases of measles
were caused by strains imported to Italy from the Czech Republic,
Germany, Switzerland, France, India, and Thailand, as shown in the
phylogenetic tree (Figure 2).
Measles is a highly infectious vaccine-preventable disease and
is still one of the leading causes of childhood mortality globally.
The WHO European Region (WHO/Europe) has adopted the goal of
eliminating measles and rubella, but despite the signiﬁcant
progress made towards this goal, the elimination of measles and
rubella in the region is yet to be achieved (World Health
Organization, 2012b; Datta et al., 2018; Adamo et al., 2017).
According to the latest assessment by the European Regional
Veriﬁcation Commission for Measles and Rubella Elimination
(RVC) of June 2018, 43 of the region’s 53 member states have
interrupted the endemic spread of measles (based on 2017
reporting). The RVC has also stated concern over poor disease
surveillance and low immunization coverage in several countries (
World Health Organization, 2018a).Member States of WHO/Europe submit monthly reports on
suspected and conﬁrmed measles and rubella cases identiﬁed
through their national disease surveillance systems to the WHO.
Between January 1 and June 31, 2018, 41 013 cases of measles were
reported to WHO/Europe or via the European Surveillance System
ECDC/TESSy, according to WHO EpiData published on August 1,
2018 (World Health Organization, 2018b). Eighty-four percent of
all the cases occurred in Ukraine (23 070), Serbia (4954), France
(2579), Greece (2130), and Italy (2029), accounting for 56%,12%, 6%,
5%, and 5%, respectively.
During the same period, a total of 1748 measles virus sequences
were reported by the reference laboratories of the WHO/Europe,
according to the MeaNS database as of July 19, 2018. The genotypes
identiﬁed throughout Europe were B3 (n = 952), D8 (n = 790), D9
(n = 5), and A (n = 1). Genotype B3 included several lineages,
comprising the more widespread WHO strain MVs/Dublin.IRL/
8.16/ and other B3 named strain MVs/SaintDenis.FRA/36.17/.
Named strains belonging to genotype D8 were MVs/GirSomnath.
IND/42.16/, MVs/Herborn.DEU/05.17/, MVs/Cambridge.GBR/5.16/,
MVs/Victoria.AUS/6.11/, and MVs/Hulu Langat.MYS/26.11/.
Virus characterization (by sequencing and information about
genotypes) is considered essential to verify the status of measles
elimination in Europe. Furthermore, monitoring of named strains
with epidemiological information for adequate case classiﬁcation
and characterization of the chains of transmission allows an
understanding of the picture of measles circulation. Genetic data
describing virus variants represent a key component of the
veriﬁcation of elimination of indigenous measles. It is also an
invaluable tool in public health investigations, both to establish
whether connections exist between concurrent measles cases and
to indicate possible sources of importations from endemic
countries, such as Italy.
Epidemiological data from European measles surveillance show
that measles is currently endemic in several European countries.
The analysis of epidemiological and genetic data from several
Italian cases conﬁrms that Italy imported measles from some of
these countries (Figure 2). Moreover, data from MeaNS show that
the named strain MVs/Dublin.IRL/8.16/ was imported from Italy to
Mexico (February 2018) and to the USA (April 2018). This strain was
also identiﬁed in the UK at the beginning of 2018 in patients
returning from Italy. This demonstrates that when unvaccinated
individuals travel to endemic countries where outbreaks are
ongoing, the cross-border transmission between member states of
the same WHO region and between different WHO regions is an
Figure 2. Phylogenetic tree constructed by using the Maximum Likelihood method
based on the Kimura 2-parameter model. The evolutionary analyses were
conducted in MEGA7. The percentage of trees in which the associated taxa
clustered together is shown next to the branches. The tree is drawn to scale, with
branch lengths measured in the number of substitutions per site. Number of
identical sequences identiﬁed in the same province by the same week is reported.
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during 2018 can support measles surveillance in countries in the
WHO European Region to better identify chains of transmission
outside of Italy and monitor the circulation of the virus.
It is important to raise awareness in the population to the fact
that measles is circulating in various European countries and to
encourage people to check their measles vaccination status,
particularly before travelling abroad, especially in the summer
when the number of people travelling increases.
Two doses of measles-containing vaccine are 97% effective
against measles. The target immunization coverage set by the
WHO for the second dose of measles-containing vaccine is 95%;
however, 20 of 27 European countries have rates below that level,including Italy (World Health Organization, 2017). European
travellers should follow the recent message put out by European
Centre for Disease Prevention and Control (ECDC) reminding
people to check their MMR status before travelling, to fully protect
a community from the disease, including persons who have
contraindications to the vaccine or who do not respond to the
vaccine.
Acknowledgements
The authors wish to thank Dr Antonietta Filia, Dr Antonino
Bella, Dr Martina Del Manso, Dr M. Cristina Rota at the Infectious
Diseases Epidemiology Unit of the National Health Institute to
manage epidemiological data; the staff in local health authorities
involved in outbreaks investigation, sampling and reporting; Drs
Francesca Rovida, Silvia Bianchi, Licia Bordi, Eleonora Lalle, Giulia
Piccirilli, Anna Morea, Monia Pacenti of MoRoNet sub-national
labs; Alessia Caratelli, Daniela Casale, Valentina Cecchetti, Sabrina
Tocchio for secretariat activities; Paolo De Leo, Ambrogio Carlei for
logistic activity; Dr Emilio D’Ugo and Antonio Giurgola for friendly
support. We are grateful to Drs E. Brown and David Williams
(Public Health England, United Kingdom) for the support by
Measles Nucleotide Surveillance (MeaNS) database; Ms Emilie
Charpentier for making available sequences identiﬁed in Serbia.
We are especially grateful to Dr Myriam Corrine Ben Mamou of the
WHO/Europe and Dr Stefania Iannazzo of Italian Ministry of Health
for providing support to the activities of the National Reference Lab
and to Prof Giovanni Rezza for revise the manuscript.
Funding source
None.
Ethical approval
Approval was not required.
Conﬂict of interest
No conﬂict of interest to declare.
References
Adamo G, Sturabotti G, D’Andrea E, Baccolini V, Romano F, Iannazzo S, et al. The end
of measles and congenital rubella: an achievable dream?. Ann Iq 2017;29
(January–February (1)):1–26.
Datta SS, O’Connor PM, Jankovic D, Muscat M, Ben Mamou MC, Singh S, et al.
Progress and challenges in measles and rubella elimination in the WHO
European Region. Vaccine 2018;36(August (36)):5408–15.
Istituto Superiore di Sanità (ISS). EpiCentro portal. Morbillo in Italia: Bollettino
settimanale. [Measles in Italy: weekly bulletin]. Rome: ISS, 43 Lug 2018. Italian.
2018 Available from: http://www.epicentro.iss.it/problemi/morbillo/bollettino/
RM_News_2018_43.pdf.
Istituto Superiore di Sanità (ISS). MoRoNet: la rete nazionale di laboratori di
riferimento per il morbillo e la rosolia. Not Ist Sup Sanità 2018b;30(3):11–3.
Magurano F, Baggieri M, Fortuna C, Bella A, Filia A, Rota MC, et al. Measles
elimination in Italy: data from laboratory activity, 2011-2013. J Clin Virol
2015;64(March):34–9.
Rota PA, Brown K, Mankertz A, Santibanez S, Shulga S, Muller CP, et al. Global
distribution of measles genotypes and measles molecular epidemiology. J Infect
Dis 2011;204(1) Suppl. 1, S514–23.
World Health Organization. Measles virus nomenclature update: 2012. Wkly
Epidemiol Rec 2012a;87(9):73–81.
World Health Organization. Global measles and rubella. Strategic plan 2012-2020.
Geneva: WHO; 2012 Available from: http://apps.who.int/iris/bitstream/10665/
44855/1/9789241503396_eng.pdf.
World Health Organization. Measles vaccines: WHO position paper—April 2017.
Wkly Epidemiol Rec 2017;92:205–28.
World Health Organization. 7th meeting of the European Regional Veriﬁcation
Commission for Measles and Rubella Elimination (RVC). Report. 2018.
World Health Organization. WHO EpiData. 2018 No. 7/2018, [http://www.euro.who.
int/__data/assets/pdf_ﬁle/0008/378602/epi-data-jul2017-jun2018-eng.pdf?
ua=1].
